Rockwell Medical, Inc. — FY 2019 Form 10-K
Reporting period: Fiscal year ended December 31, 2019, compared with FY 2018. This is an annual filing; it does not provide a clear standalone fourth-quarter financial summary.
Business context
Rockwell combines a hemodialysis concentrate business with a developing biopharmaceutical business focused on anemia and kidney disease. Concentrates represented approximately 96% of FY 2019 revenue. The company estimated it supplied approximately 25% of the U.S. dialysis-concentrate market. Dialysate Triferic, its iron-replacement therapy, launched in the U.S. in May 2019; the company submitted an NDA for I.V. Triferic in May 2019.
Key financial results
| Metric | FY 2019 | FY 2018 |
|---|---|---|
| Revenue | $61.3 million | $63.4 million |
| Gross profit (loss) | $2.8 million; 4.6% margin | $(1.6) million; (2.5)% margin |
| Operating loss | $(34.5) million | $(32.4) million |
| Net loss | $(34.1) million | $(32.1) million |
| Net loss per share | $(0.56) | $(0.61) |
| Cash used in operating activities | $(27.3) million | $(20.4) million |
At year-end, cash and cash equivalents were $11.8 million and available-for-sale investments were $14.3 million, totaling approximately $26.0 million. Working capital was $24.5 million; total liabilities were $24.0 million and stockholders’ equity was $20.3 million. Reported year-end financing obligations included a $0.8 million insurance note and lease liabilities totaling $3.3 million.
Material changes and operating trends
- Revenue declined 3.3%, primarily because lower international concentrate sales more than offset increased sales under the DaVita contract. Triferic revenue was approximately $0.5 million, including U.S. product sales and recognized license revenue.
- Gross profit improved by $4.4 million, mainly because inventory-reserve charges were lower than in 2018; increased labor, materials, and overhead costs reduced concentrate-business gross profit.
- Selling and marketing expense rose to $9.1 million from $1.0 million as Rockwell built its commercial organization for Triferic. Research and product development expense increased to $6.9 million from $5.6 million.
- Operating cash use increased by $6.8 million. The company reported an accumulated deficit of $306.5 million.
- Sales were concentrated: DaVita accounted for 49% of 2019 sales, Baxter approximately 27%, and Nipro 9%. The new DaVita purchase agreement began in 2019 and has an initial term through December 31, 2023.
Outlook, financing, and key risks
- Management expected an FDA decision on I.V. Triferic by March 28, 2020 and anticipated a U.S. launch in Q4 2020, subject to approval. The filing provides no quantified revenue or earnings guidance.
- CMS’s revised rules made I.V. Triferic ineligible for TDAPA add-on reimbursement, according to the company. Dialysate Triferic is reimbursed within the dialysis bundle; the company cautions this may slow adoption because providers receive no separate payment.
- After year-end, Rockwell raised approximately $8.0 million net through an equity offering. On March 16, 2020, it drew $22.5 million of a potential $35.0 million loan, receiving approximately $21 million net; the additional $12.5 million is milestone-dependent. The initial cash interest rate was 8.75%, and the loan matures in 2025. Management said these financings provided funds for at least 12 months from the filing date, while noting that longer-term plans require additional capital. Equity issuance is dilutive; the loan carries interest, covenants, and repayment obligations.
- Triferic inventory exposure remains material: the filing reported $3.5 million of gross Triferic inventory against which $2.8 million was reserved at year-end. Slow adoption or expiry could require further write-offs.
- Other risks include dependence on a small number of concentrate customers, competition and pricing pressure, reliance on contract manufacturers, and uncertainty around reimbursement and commercial adoption. The filing also identified potential disruption from the coronavirus outbreak to clinical trials, supply, and demand.
- A supplier demanded $3.0 million in penalties plus raw-material costs over alleged minimum-purchase shortfalls; Rockwell said it had defenses, and no lawsuit had been filed. The securities class-action settlement totaled $3.7 million, with Rockwell expected to contribute approximately $0.4 million; court approval followed in February 2020. Derivative actions remained in settlement discussions. An SEC investigation was ongoing.
- The independent auditor gave an unqualified opinion on the financial statements but an adverse opinion on internal control over financial reporting. Material weaknesses involved ERP access, change-management, and segregation-of-duties controls; management’s remediation efforts were ongoing.
- A Baxter agreement trigger could require repayment of 25% of its $20 million upfront fee during 2019–2021, subject to the agreement’s terms. The filing also disclosed approximately $24.9 million of purchase obligations through 2020.
Important facts for investors to verify
- FDA action on I.V. Triferic, any additional regulatory requirements, and the timing and terms of any launch.
- Actual Triferic adoption, sales, inventory usage before expiry, and any further inventory reserves or write-offs.
- Cash burn versus available liquidity, milestone availability under the loan, financing covenants, and future capital needs.
- Whether the supplier claim and derivative litigation are resolved, and the outcome of the SEC investigation.
- Progress in remediating internal-control material weaknesses and auditor findings.
- Customer concentration, DaVita and Baxter contract performance, and the impact of bundled reimbursement on margins and sales.